Cannabis affects different people differently. These are the population gates and frequency thresholds that earn extra caution.
Section 1
Hard population gates
If you're under 25
Adolescent and young-adult brains are still developing prefrontal circuits responsible for executive function and emotional regulation. A 2024 cohort study found cannabis use associated with over 11x greater risk of psychotic disorder during adolescence. The risk drops in young adulthood but remains elevated. The platform recommends delaying cannabis use until at least age 21, ideally 25, and avoiding high-potency THC or concentrates entirely under 25.
Lancet Psychiatry 2024 cohort study
If you are pregnant or lactating
There is no established safe level of cannabis use during pregnancy or breastfeeding. THC crosses the placental barrier and is present in breast milk. Cannabis exposure during pregnancy is associated with reduced birth weight, impaired neurodevelopmental outcomes, and other measurable risks. The platform does not present any benefit framing for cannabis in this population — only the safety gate.
ACOG / CDC guidelines
If you have personal or family psychosis history
A 2025 study from Ontario found that 18.9% of incident schizophrenia cases among younger males were associated with cannabis use disorder. Personal history of psychosis, bipolar disorder with psychotic features, or family history of schizophrenia spectrum disorders substantially elevates the psychiatric destabilization risk from cannabis use, especially high-potency THC.
JAMA Network Open 2025
If you take prescription medications
Cannabis — and CBD in particular — affects liver enzymes that metabolize many medications, including CYP3A4, CYP2C9, CYP2C19, and CYP1A2, plus the P-glycoprotein transporter. This can alter the effective dose of blood thinners, antidepressants, anti-epileptics, immunosuppressants, and many others. CADDRA notes that ADHD medications may appear less effective when used with cannabis. Anyone on prescription medications should review interactions with a clinician before adding cannabis.
FDA / CADDRA / NCBI drug interaction databases
If you are a federal employee, military, or VA patient
Federal law still classifies cannabis as Schedule I. Federal employees, active military, contractors with security clearances, and VA-enrolled patients face employment, benefits, and care implications from cannabis use even in states where it's legal. The VA/DoD 2023 PTSD guideline recommends against cannabis for PTSD treatment. Travel across state lines, federal property, and federal employment all carry distinct legal exposure.
VA/DoD 2023 PTSD CPG / 21 USC 812
Section 2
Frequency thresholds matter
How often you use cannabis substantially changes your risk profile for cannabis use disorder. The 2022 meta-analysis on CUD risk thresholds quantified this:
Frequency
Relative risk of CUD
Yearly use
~2.03x
Monthly use
~4.12x
Weekly use
~8.37x
Daily use
~16.99x
These are relative risks compared to non-users. They do not predict whether any individual will develop CUD — but they document that the curve steepens sharply with frequency. The platform's harm-reduction framing recommends maintaining the lowest-frequency pattern that achieves your goal.
Leung et al, Drug and Alcohol Dependence 2022
Section 3
Product disclosure framework
Not all “cannabis” is the same. The platform distinguishes four product categories with materially different evidence and risk profiles:
CBD-rich (low THC, high CBD)
Weaker evidence for pain. May affect liver enzymes that metabolize medications. FDA has approved purified CBD (Epidiolex) for specific seizure disorders; most marketed CBD products are not equivalent to the trial formulations.
Balanced THC:CBD
Moderate evidence for short-term improvements in neuropathic-predominant chronic pain. Best-studied formulation is oral spray. Dizziness, sedation, nausea are common.
THC-dominant
Wider range of effects but stronger risk profile for psychiatric destabilization, cognitive impairment, and dependence. Risk scales with potency.
Concentrate / high-potency (>50% THC)
Distinct risk signal especially in adolescents and people with psychosis vulnerability. Risk of acute psychiatric events and cannabis use disorder is substantially elevated.
Section 4
Lower-risk use guidelines
When cannabis use is happening, harm reduction matters more than abstinence ideology. The 2022 Lower-Risk Cannabis Use Guidelines (Fischer et al) emphasize:
Delay initiation until after adolescence.
Avoid high-potency products and concentrates.
Avoid daily or near-daily use patterns.
Avoid smoked routes where possible (consider oral or sublingual alternatives).
Do not drive within four to six hours of use.
Combining cannabis with alcohol or other CNS depressants carries compounded risk.
FIND YOUR PEOPLE
Cannabis isn't navigated alone
Local chapters, justice work, and direct support for those still inside. Verified national organizations.
POLICY + LAW
NORML
State-by-state legal tracker. Local chapters in 30+ states. Working to reform marijuana laws since 1970.
Thousands remain incarcerated for what's now a multi-billion-dollar industry. Direct legal support, clemency campaigns, and reentry assistance. 501(c)(3) EIN 83-4502829.
Bringing light to dark cells. Commissary funds, books, family outreach for non-violent cannabis prisoners. Founded 2015 by Stephanie Landa. Volunteer-driven 501(c)(3).